Related Experiment Video
Updated: Nov 4, 2025
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
2.6K
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Kathleen D Engelman1, Alan N Engelman2,3
1MassBiologics, University of Massachusetts Medical School, 460 Walk Hill Street, Boston, Massachusetts 02126, United States.
Biochemistry
|May 24, 2021
Summary
Long-acting injectable cabotegravir (CAB-LA) shows promise for HIV-1 prevention. This integrase inhibitor offers a more effective alternative to daily oral pre-exposure prophylaxis (PrEP), addressing adherence challenges.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- HIV-1 remains a global health challenge, with current prevention strategies like vaccination being limited.
- Antiretroviral therapies, including daily oral medications, are effective but face adherence issues.
- Long-acting injectable (LA) inhibitors offer a potential solution to improve adherence and efficacy.
Purpose of the Study:
- To review the development and clinical application of long-acting injectable cabotegravir (CAB-LA) for HIV-1 prevention.
- To examine the biochemical mechanisms and clinical trial results of CAB-LA.
- To discuss the potential and challenges of CAB-LA for pre-exposure prophylaxis (PrEP).
Main Methods:
- Biochemical analysis of HIV-1 integrase and its inhibition.
- Review of recent clinical trials evaluating CAB-LA efficacy and safety.
- Examination of bench-to-bedside translation of CAB-LA treatment.
Main Results:
- CAB-LA, an integrase inhibitor, has demonstrated superior efficacy in preventing HIV-1 acquisition compared to daily oral antiretrovirals in clinical trials.
- LA injectables address adherence challenges associated with daily oral regimens.
- CAB-LA shows significant promise as a novel PrEP strategy.
Conclusions:
- CAB-LA represents a significant advancement in HIV-1 prevention, offering a highly effective long-acting option.
- Further research and implementation strategies are needed to overcome challenges and maximize the benefits of CAB-LA for HIV/AIDS PrEP.
- The development of CAB-LA highlights the potential of long-acting antiretroviral therapies.
Related Concept Videos
01:10Retrovirus Life Cycles
48.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.0K
02:33Retroviruses
13.2K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
13.2K
01:29Subviral Agents
264
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
264
01:01Dosage Regimen: Fixed Dose
2.1K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.1K
01:15Drug Dosage Regimen: Overview
4.1K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.1K
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
40
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
40